Lexeo Therapeutics (NASDAQ:LXEO) Sees Unusually-High Trading Volume

Lexeo Therapeutics, Inc. (NASDAQ:LXEOGet Free Report) shares saw unusually-high trading volume on Friday . Approximately 123,752 shares changed hands during trading, an increase of 1% from the previous session’s volume of 122,505 shares.The stock last traded at $15.98 and had previously closed at $15.68.

Wall Street Analysts Forecast Growth

LXEO has been the topic of several recent analyst reports. HC Wainwright initiated coverage on Lexeo Therapeutics in a research report on Thursday, June 6th. They set a “buy” rating and a $22.00 target price on the stock. Baird R W raised Lexeo Therapeutics to a “strong-buy” rating in a report on Thursday, June 13th. Finally, Robert W. Baird initiated coverage on Lexeo Therapeutics in a report on Thursday, June 13th. They issued an “outperform” rating and a $28.00 price objective on the stock. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Lexeo Therapeutics currently has a consensus rating of “Buy” and an average price target of $22.00.

Read Our Latest Research Report on Lexeo Therapeutics

Lexeo Therapeutics Stock Performance

The stock has a market capitalization of $519.46 million and a price-to-earnings ratio of -0.70. The firm has a fifty day moving average of $14.55 and a 200 day moving average of $14.86. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16.

Lexeo Therapeutics (NASDAQ:LXEOGet Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.01). On average, sell-side analysts anticipate that Lexeo Therapeutics, Inc. will post -2.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new position in Lexeo Therapeutics during the first quarter worth $75,000. American International Group Inc. acquired a new position in Lexeo Therapeutics during the first quarter worth $79,000. Cornell University acquired a new position in Lexeo Therapeutics during the first quarter worth $1,980,000. Vanguard Group Inc. boosted its stake in Lexeo Therapeutics by 15.8% during the first quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock worth $7,554,000 after buying an additional 65,573 shares during the last quarter. Finally, Blackstone Inc. purchased a new stake in Lexeo Therapeutics in the fourth quarter valued at $9,342,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

See Also

Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.